Glaucoma Therapeutics Market Forecast and Analysis to 2030
Glaucoma Therapeutics Market |
Glaucoma
is the leading cause of irreversible vision loss throughout the world. Glaucoma
refers to a group of diseases, each with its own set of risk factors, symptoms,
treatment, and prognosis. All types of glaucoma are distinguished by the loss
of retinal ganglion cells (RGCs) and their axons, which results in cupping of
the optic nerve head. This causes optic nerve damage and loss of visual field.
As a result, glaucoma treatment options revolve around lowering the IOP.
Although current treatment options can slow the progression of glaucoma, it is
not possible to reverse vision loss caused by the disease.
According
to Coherent Market Insights the Glaucoma
Therapeutics Market Global Industry Insights, Trends, Outlook, and
Opportunity Analysis, 2022-2028
The
degradation of retinal nerve fibre layers and retinal ganglion cells that
underlies glaucoma, a condition of progressive optic neuropathies, may modify
the optical nerve head. High intraocular pressure (IOP) is the main risk factor
because it can harm the optic nerve, and prolonged harm to this organ can
result in irreversible visual field abnormalities, vision loss, and blindness.
The most common cause of permanent blindness worldwide is glaucoma. Gender,
race, myopia, family history, genetics, age and frailty, vasospasm, smoking,
systemic hypotension and hypertension, obstructive sleep apnea syndrome,
migraine, steroid use, and higher IOP are all risk factors. However, the latter
is the most important. These elements will increase the s demand for Glaucoma
Therapeutics Market,
The demand for glaucoma treatments will increase as more people in the area develop glaucoma of various sorts. The Glaucoma Therapeutics Market size will increase due to rising knowledge of eye care, as well as the accompanying diagnoses and treatments. Additionally, the region's industry growth will be supported by the strong presence of major market players who are involved in the discovery of new drugs and the approval of products.
Comments
Post a Comment